The public discussion surrounding GLP-1 medications remains focused on external transformation. Across medical settings and media, rapid weight loss gets celebrated as an automatic win for health. You will routinely hear claims that these medications will make you feel better, improve your health, or eliminate food noise entirely. But what does weight-inclusive care in the GLP-1 era actually look like? Is it safe to use these medications strictly for weight loss? Are they truly leading to long-term health, and is there a legitimate place for them in eating disorder treatment?
For years, clinical understanding and public awareness were gradually shifting toward the reality that chronic dieting does not work. Yet today, roughly 12% of adults in the United States report using GLP-1 medications for weight loss. Parents, siblings, friends, and doctors are prescribing or taking them in record numbers.
The widespread culture surrounding GLP-1s has brought the outdated myth that thinner is better back to the center of social media and healthcare discussions. This rapid cultural resurgence of weight-centric messaging poses a severe threat when clinicians and clients are actively trying to dismantle diet culture.
The weight-neutral approach to eating disorder treatment at the Kahm Center centers on a basic physiological fact: external appearance tells us very little about internal biological function. A person can live in a body that fits societal standards while experiencing severe cellular deficits, metabolic adaptation, and profound psychological distress.
When GLP-1 medications intersect with eating disorder vulnerability, the physiological and psychological risks go far beyond simple side effects.
How Do GLP-1 Medications Work?
To understand why these medications carry unique risks for eating disorder recovery, it helps to look at what they actually do in the body. Glucagon-like peptide-1 is a natural gut hormone that regulates blood sugar, slows stomach emptying, and signals fullness to the brain. GLP-1 receptor agonist medications mimic this hormone, acting as synthetic signaling agents designed to reduce appetite and suppress cravings.
These medications have proven genuinely helpful for adults with Type 2 diabetes who need to lower blood sugar when standard treatments like metformin are insufficient, with roughly 26% of adults with Type 2 diabetes currently using them. Emerging research also points to benefits for managing autoimmune conditions, kidney disease, and specific neurodegenerative disorders.
But outside of these specific clinical applications, there are numerous, serious concerns. For someone vulnerable to or recovering from a serious clinical eating disorder—such as anorexia nervosa, bulimia nervosa, or binge eating disorder—introducing a powerful chemical appetite suppressant alters the entire recovery landscape. By overriding natural signaling pathways, these medications disrupt the foundational work of rebuilding biological trust and metabolic stability.
The Relapse Risk: How Chemical Appetite Suppression Mimics Severe Restriction
When these medications slow digestion, the stomach stays full longer, sending signals to the brain that the body is fine even when it is actually running on empty. This false sense of fullness makes it easy for someone in recovery to slip back into skipping meals without noticing the shift. For many, that constant physical fullness triggers the exact same distress felt during weight restoration in treatment, or brings back the uncomfortable memory of eating after a period of starving. Both can trigger intense fear and bring back old behaviors.
Most people still think of anorexia nervosa when they think of eating disorders, and of severe caloric restriction and distorted thinking about food and body. But undernourishment is also what often drives bulimia and binge eating. Quieting hunger doesn't mean the body doesn't need food; it just postpones the body's reaction. When the medication wears off or the dose shifts, unaddressed starvation often leads to intense rebound binges, keeping the cycle of restriction, shame, and reactive eating alive.
As the body runs out of energy, the disorder returns. Starvation changes how the brain works long before someone notices they are slipping. Thoughts about food start taking over, anxiety creeps up, and emotions go flat. That numbing can feel like relief—a familiar coping mechanism from when the illness was active. Because taking a prescription gives a convenient excuse to turn down food, people close to them rarely get suspicious, allowing a relapse to hide in plain sight.
The emotional strain grows fast. As energy drops, people pull away from others. Social gatherings feel exhausting, eating around people brings up dread, and there is little mental energy left to fight off disordered thoughts. A standard prescription can quickly turn into a full relapse, where physical hunger and emotional pain feed off each other.
For anyone under 26, this forced restriction carries extra risk by disrupting brain growth alongside physical development. Silencing the body's warning systems destroys the trust and body connection that healing depends on.
Dismantling Weight Stigma: Why "Healthy on the Outside" Is a Dangerous Myth
Weight bias in healthcare operates on a single, flawed premise: higher body weight equals poor health, and weight loss equals healing. Because of pervasive stigma, individuals in larger bodies are frequently prescribed GLP-1s without a real assessment of their history with food, past dieting, or active eating behaviors. This stigma also obscures how eating disorders develop and persist in the first place.
Binge eating, for example, is routinely pathologized and blamed on a lack of willpower, while the underlying cycle of chronic dieting and social pressure for thinness gets ignored. Prescribing a medication to stop bingeing treats a surface symptom while weaponizing weight bias against the patient.
When someone in a larger body loses weight on a GLP-1, providers often praise the result while the warning signs—signs like severe fatigue, malnutrition, social withdrawal, or constant thoughts about food—are routinely brushed aside. In a smaller body, these exact same manifestations would immediately trigger clinical intervention and concern. But in a larger body, shrinking the physical frame is treated as automatically worth any physical or mental risk.
This glaring double standard reinforces the harmful belief that achieving thinness is paramount, while the actual physical and psychological consequences of rapid weight loss are treated as secondary.
Reframing Health: Biological Function over Weight Metrics
GLP-1 medications serve clear medical purposes and are likely here to stay, supported by extensive research for conditions like Type 2 diabetes. However, the long-term safety and effectiveness of using GLP-1s, especially for those with an eating disorder, remains unclear. In a culture that routinely mistreats people in larger bodies in both daily life and inside doctor's offices, the pressure to use these drugs to shrink one's body is completely understandable. But when weight loss becomes the sole measure of success, real health issues fall through the cracks.
People in larger bodies struggling with severe restriction are frequently overlooked, misdiagnosed with binge eating disorder, or labeled as atypical simply because they do not fit the traditional visual image of starvation. Healthcare systems have defaulted back to using outdated ideal body weight and BMI charts as strict standards for health, ignoring individual genetics or growth history.
Relying on surface numbers or standard blood panels fails to show internal tissue loss, metabolic slowdown, or the toll of ongoing energy deficits. Meanwhile, insurance companies continue using those same arbitrary BMI thresholds to dictate coverage and determine who qualifies for care.
Improving outcomes requires a broader understanding of how eating disorders present, along with better access to comprehensive care. Aligning insurance coverage and clinical evaluations with accurate, internal measures of health—rather than scale weight—allows providers to catch warning signs early and offer genuine support. Expanding care to treat the whole person is essential for lasting recovery.
In Part 2 of this series, we will examine clinical treatment considerations for GLP-1 complications and explore how advanced diagnostic testing supports recovery. If you or a loved one are struggling with an eating disorder, food preoccupation, or the physical impact of GLP-1 medications, reach out to learn more about our higher-level care programs in Burlington, VT.
Clinically Reviewed By
Nick Kahm, PhD
Co-Founder
Nick Kahm, a former philosophy faculty member at St. Michael's College in Colchester, VT, transitioned from academia to running the Kahm Clinic with his mother. He started the clinic to train dietitians in using Metabolic Testing and Body Composition Analysis for helping people with eating disorders. Now, he is enthusiastic about expanding eating disorder treatment through the Kahm Center for Eating Disorders in Vermont.
